Welcome to MOLOGEN AG

With new and unique technologies and active substances, the biotech company MOLOGEN is one of the pioneers in the field of immunotherapy. Our main focus is on oncology and severe infectious diseases.

We use latest expertise from the fields of molecular medicine and immunology to enable the human immune system to fight the disease or disease pathogen itself - an approach that we are promoting with great conviction.

Using our own, patent-protected technology platforms, we are able to produce highly effective and extremely well-tolerated drugs against diseases with high unmet medical need. 

DR. IGNACIO FAUS CEO MOLOGEN AG

• Three-month exclusivity period for negotiations with ONCOLOGIE on the global assignment of lefitolimod expired without agreement • During the exclusivity period ONCOLOGIE presented new financial terms for the transaction that were vastly inferior to those agreed in the non-binding term sheet signed by the two companies on August 15th, 2018;... [more]

Publication of insider information as per Article 17 of (EU) Regulation No. 596/2014 The biopharmaceutical company MOLOGEN AG (ISIN DE000A2LQ900, WKN A2LQ90) decided to terminate the negotiations with ONCOLOGIE Inc. on the conclusion of definitive transaction documentation for the global assignment of all intellectual property and other rights in... [more]

Annual Report 2017

Download pdf

Quarterly Statement as at 31 March 2018

Download pdf

Half-Yearly Financial Statement as at 30 June 2018

Download pdf

Quarterly Statement as at 30 September 2018

Download pdf